Phase II Study on the Efficacy and Safety of the EP1 Receptor Antagonist ONO-8539 for Nonneurogenic Overactive Bladder Syndrome
Christopher R. Chapple(Sheffield Teaching Hospitals NHS Foundation Trust), Steve Deacon(Ono Pharmaceutical (United Kingdom)), Michael Small(The University of Western Australia), Takahiro Masuda(Jichi Medical University), Piotr Radziszewski(Medical University of Warsaw), Paul Abrams(Southmead Hospital), T. Kuwayama(Ono Pharmaceutical (United Kingdom)), Karl‐Erik Andersson(Forest Institute)
Cited by 35
Related Papers
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era
|European Urology|2020|313
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
|American Journal of Physiology-Renal Physiology|2012|158
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
|Physiological Reports|2020|135